Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 7, 2022

BP Elements

  • BioPharm International's BP Elements, April 2022
  • Volume 1
  • Issue 4

PerkinElmer Introduces the HTRF and AlphaLISA Assay Kits

PerkinElmer’s HTRF and AlphaLISA assay kits are designed to detect and quantify CHO host cell protein impurities.

PerkinElmer has released two ready-to-use no-wash assay kits in April 2022, the homogeneous time-resolved fluorescence (HTRF) and AlphaLISA. The assay kits are designed to quickly and easily detect and quantify Chinese hamster ovary (CHO) host cell protein (HCP) impurities during the biopharmaceutical manufacturing process, which can prevent immunogenicity and reduce potency, stability, and overall effectiveness of a drug.

According to an April 4, 2022 company press release, HTRF and AlphaLISA are the first kits on the market to be designed for the ready-to-use, homogenous, no-wash assays used in CHO HCP impurity detection. They are also designed to deliver a streamlined workflow, broader dynamic range, and higher sensitivity than traditional multi-step enzyme-linked immunosorbent assays. The kits can be miniaturized to a small sample volume, increasing throughput to 384-well plates.

"The ability to quickly and easily detect, quantify, and subsequently eliminate CHO HCP impurities during biopharmaceuticals manufacturing has continued to be a key challenge," said Alan Fletcher, senior vice-president life sciences, PerkinElmer, in the press release. "These innovative HTRF and AlphaLISA assay kits are designed to make this critical step more effective and efficient within existing workflows and contribute to quality control and successful biotherapeutics."

Source: PerkinElmer


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.